Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate
Over the last two decades, Big Pharma has tried to introduce numerous drugs to combat Alzheimer's disease. Almost all of these drugs have focused on amyloid plaques in the brain. If we remove the plaques, the theory goes, patients will get better. And patients have not gotten better. It's been 20 years of failure after failure after failure in the clinical trials.
Now a tiny biotech, Cassava Sciences (NASDAQ: SAVA) has emerged with a new theory. Instead of focusing on amyloid plaques on the brain, Cassava wants to fix a mutating protein known as Filamin A. In this video from Motley Fool Live, recorded on July 30, Motley Fool editor and analyst Olivia Zitkus and Fool contributor Taylor Carmichael discuss simufilam, the new therapy from Cassava.
Source Fool.com
